Memantinhydrochlorid Stada (Memantine Hydrochloride)

Memantine Hydrochloride acts on the glutamatergic pathway and is used in dementia management.

• Alzheimer’s disease (moderate to severe): helps maintain cognitive function and daily living activities.
• Alzheimer’s disease (mild to moderate) as add‑on therapy: provides additional symptomatic benefit when combined with cholinesterase inhibitors.
• Dementia associated with Parkinson’s disease (off‑label): may improve cognition and motor function.

• Memantine Hydrochloride is a non‑competitive antagonist of the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by chronic glutamate stimulation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: transient sensation of light‑headedness.
• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements.
• Fatigue: feeling of tiredness or lack of energy.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Hallucinations or psychosis: visual or auditory disturbances.
• Suicidal thoughts: emergence of depressive ideation.

When prescribing Memantinhydrochlorid Stada, clinicians should consider several safety aspects.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• History of seizures: use with caution and observe for increased seizure activity.
• Concomitant NMDA antagonists: avoid combined use to reduce risk of additive CNS effects.
• Pregnancy: safety not established; weigh potential benefits against risks.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Amantadine: combined use can increase CNS side effects.
• Ketamine: additive NMDA antagonism may enhance neurotoxicity.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of peripheral edema.
• Diuretics: monitor electrolyte balance and blood pressure.
• Anticholinergic agents: can exacerbate confusion or cognitive decline.